Comparison Of Two Tablet Formulations Of SB-568859
NCT00470145
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
28
Enrollment
INDUSTRY
Sponsor class
Conditions
Atherosclerosis
Interventions
DRUG:
SB-568859
Sponsor
GlaxoSmithKline